During this breaking news community webinar, Edgewise provides an update on the recently released topline results from its CANYON double-blind, randomized, placebo-controlled design to investigate the effect of sevasemten on individuals with Becker muscular dystrophy. Edgewise’s VP, Patient Advocacy and External Innovation, Abby Bronson, MBA and Chief Medical Officer Joanne Donovan, MD, PhD, gave context and greater detail to the the topline results and answered questions from the community.